One of the oldest treatment options in rheumatology, colchicine, may be an effective and inexpensive treatment to prevent complications in non-hospitalized patients with COVID-19, particularly in men, according to the results of large global study.
FDA Approves IVIG to Treat Adults with Dermatomyositis
In July, the FDA approved the use of Octagam 10%, an intravenous immunoglobulin solution, to treat dermatomyositis in adults after an international study demonstrated the treatment’s safety and efficacy.
2 Cases of SLE-Associated Diffuse Alveolar Hemorrhage
Pulmonary manifestations in patients with systemic lupus erythematosus (SLE) include pleuritis, acute pneumonitis, interstitial lung disease, pulmonary arterial hypertension, shrinking lung syndrome and diffuse alveolar hemorrhage (DAH). DAH is a rare, but devastating, complication of SLE, with high mortality rates. The incidence of DAH in SLE ranges from 0.6% to 5.4%, but the mortality rate…
Coding Corner: Interprofessional Telephone/Internet/Electronic Health Record Assessment & Management
Example 1 A cardiologist contacts a rheumatologist concerning a lupus patient. The rheumatologist sees the patient four weeks later for a complete examination. A 20-minute call is initiated to review the findings and the patient’s chart with the cardiologist. After the call is completed, the rheumatologist completes a verbal and written report to the patient’s…
Make an Impact: Join Our Community of Donors
The Rheumatology Research Foundation is proud to announce the launch of RheumBuilders, a new community of monthly donors, and the relaunch of its Legacy Society, a community of donors who have included the Foundation in their wills or estate plans. These initiatives are designed to deepen the Foundation’s commitment to rheumatology research and patient care,…
Coming in September … Rheumatic Disease Awareness Month
In 2016, as part of the Simple Tasks campaign, the ACR established September as Rheumatic Disease Awareness Month (RDAM) to draw attention to the 100-plus conditions under the rheumatic disease umbrella. The goal of RDAM is not only to raise public awareness, but also to increase understanding about the symptoms, risk factors, treatment options, economic…
Healthcare Extenders Can Reduce Physician Burden & Improve Patient Access & Care
In the early 1900s, the treatment for rheumatic and musculoskeletal disease (RMD) was primarily targeted at symptomatic relief and included analgesics, physical therapy, splinting and bed rest. With the discovery of methotrexate and its impact on rheumatoid arthritis (RA) management, a much-needed evolution of medications targeting disease activity began. Over the past 30 years, several…
COVID-19 Vaccination in Patients with Rheumatic Disease
With a large percentage of the U.S. population unsure whether they will get vaccinated against COVID-19, rheumatology patients remain vulnerable. On May 13, the ACR hosted a virtual town hall highlighting ways rheumatology providers might effectively approach their patients who have not yet decided to get a COVID-19 vaccine. Get the Slow Yes At the…
ACR Commends CMS Decision to Withdraw Most Favored Nation Payment Model for Part B Drugs
ATLANTA—The American College of Rheumatology (ACR) today applauded the U.S. Centers for Medicare & Medicaid Services’ (CMS) decision to withdraw a proposed rule to implement the “Most Favored Nation” (MFN) payment model for Part B drugs. Leaders felt the policy would have dramatically disrupted patient access to critical therapies needed to manage rheumatic diseases and…
The Story of the N95 Mask
On Dec. 17, 1903, at 10:35 a.m., the restraining wire was released. The Wright brothers—Orville and Wilbur—owned a bicycle sales and repair shop called the Wright Cycle Exchange, in Dayton, Ohio. At the time, the popularity of bicycles was exploding, thanks to an innovation that made them much easier (and safer) to ride. The money…
- « Previous Page
- 1
- …
- 130
- 131
- 132
- 133
- 134
- …
- 810
- Next Page »